<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:d96f64be-0440-4612-bdd8-d6b2a39efd57,g:66f88546-5521-4c57-90fd-9a536253216c,d:030c301ed5544605835a6173a767cc0b--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vrdn-20210423</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xMy9mcmFnOmY1OWEzY2ZjYjBkMTRjMmU5NTMyZDU1N2QxYmNiNGNiL3RhYmxlOmYyNWMzYWNmZjUzNDQxNzFiMjc1ZTZmNjYzY2IwNTQ4L3RhYmxlcmFuZ2U6ZjI1YzNhY2ZmNTM0NDE3MWIyNzVlNmY2NjNjYjA1NDhfMC0xLTEtMS0w_7924b8fa-ba88-4bdc-9271-095d7091211b">Viridian Therapeutics, Inc.\DE</ix:nonNumeric><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xMy9mcmFnOmY1OWEzY2ZjYjBkMTRjMmU5NTMyZDU1N2QxYmNiNGNiL3RhYmxlOmYyNWMzYWNmZjUzNDQxNzFiMjc1ZTZmNjYzY2IwNTQ4L3RhYmxlcmFuZ2U6ZjI1YzNhY2ZmNTM0NDE3MWIyNzVlNmY2NjNjYjA1NDhfMS0xLTEtMS0w_eda3226a-b6f2-4d0e-b38c-e43389db674b">false</ix:nonNumeric><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xMy9mcmFnOmY1OWEzY2ZjYjBkMTRjMmU5NTMyZDU1N2QxYmNiNGNiL3RhYmxlOmYyNWMzYWNmZjUzNDQxNzFiMjc1ZTZmNjYzY2IwNTQ4L3RhYmxlcmFuZ2U6ZjI1YzNhY2ZmNTM0NDE3MWIyNzVlNmY2NjNjYjA1NDhfNS0xLTEtMS0w_e93a26df-d220-4fce-a608-fc45bfa3c35d">0001590750</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vrdn-20210423.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-23</xbrli:startDate><xbrli:endDate>2021-04-23</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i030c301ed5544605835a6173a767cc0b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGV4dHJlZ2lvbjo3ZDQxOWM4MTgxZjg0YTNkOGI1ODk4NWI1Mzg4MGY2Nl8xMjM4_7067a1cd-20a4-40e6-9449-729c1a089dbd">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGV4dHJlZ2lvbjo3ZDQxOWM4MTgxZjg0YTNkOGI1ODk4NWI1Mzg4MGY2Nl8yMjQ_2c5e8a45-0718-4c04-87ca-a6539e0dbf39">April 23, 2021</ix:nonNumeric></span></div><div style="text-align:center"><img src="vrdn-20210423_g1.jpg" alt="vrdn-20210423_g1.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">VIRIDIAN THERAPEUTICS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.451%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6NjNmMmJmYzRhOTEzNDQ2OWFhY2EyOTk4MGMwY2FlNTgvdGFibGVyYW5nZTo2M2YyYmZjNGE5MTM0NDY5YWFjYTI5OTgwYzBjYWU1OF8wLTAtMS0xLTA_08077829-8d27-48f3-87c8-7e1314132554">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6NjNmMmJmYzRhOTEzNDQ2OWFhY2EyOTk4MGMwY2FlNTgvdGFibGVyYW5nZTo2M2YyYmZjNGE5MTM0NDY5YWFjYTI5OTgwYzBjYWU1OF8wLTItMS0xLTA_f8ed1aa3-5d86-4812-a162-c7854d603461">001-36483</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6NjNmMmJmYzRhOTEzNDQ2OWFhY2EyOTk4MGMwY2FlNTgvdGFibGVyYW5nZTo2M2YyYmZjNGE5MTM0NDY5YWFjYTI5OTgwYzBjYWU1OF8wLTQtMS0xLTA_a0e0315a-9e39-4cd3-b3ab-1607751d8252">47-1187261</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.239%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6YTJlY2ZiNTMwOTFiNDk5NDgwZGI4YjU1N2Q5ZThiNjYvdGFibGVyYW5nZTphMmVjZmI1MzA5MWI0OTk0ODBkYjhiNTU3ZDllOGI2Nl8wLTEtMS0xLTA_7240b89d-9aa6-48d7-956e-cfb094da6287">6200 Lookout Rd.</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6YTJlY2ZiNTMwOTFiNDk5NDgwZGI4YjU1N2Q5ZThiNjYvdGFibGVyYW5nZTphMmVjZmI1MzA5MWI0OTk0ODBkYjhiNTU3ZDllOGI2Nl8xLTEtMS0xLTA_1ad400df-1c56-4b59-8278-a8d7bf792ee1">Boulder,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6YTJlY2ZiNTMwOTFiNDk5NDgwZGI4YjU1N2Q5ZThiNjYvdGFibGVyYW5nZTphMmVjZmI1MzA5MWI0OTk0ODBkYjhiNTU3ZDllOGI2Nl8xLTItMS0xLTA_619cbef7-8a83-4c6c-9bf2-ee713fe5c059">CO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6YTJlY2ZiNTMwOTFiNDk5NDgwZGI4YjU1N2Q5ZThiNjYvdGFibGVyYW5nZTphMmVjZmI1MzA5MWI0OTk0ODBkYjhiNTU3ZDllOGI2Nl8xLTUtMS0xLTA_fa22702c-66ab-4ac9-ac91-5022b06c27b1">80301</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGV4dHJlZ2lvbjo3ZDQxOWM4MTgxZjg0YTNkOGI1ODk4NWI1Mzg4MGY2Nl8xMjQx_4c5f94a3-5891-42cd-a6c6-05fdb7e70b0c">720</ix:nonNumeric>) <ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGV4dHJlZ2lvbjo3ZDQxOWM4MTgxZjg0YTNkOGI1ODk4NWI1Mzg4MGY2Nl8xMjQy_c8c28c35-4c23-4565-b1ce-22a6d03c4e33">643-5200</ix:nonNumeric>&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:2.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6NWVhNDc1NDkwMDg5NGJmNTk1NGNhNjEyMzU1ZjIwYzAvdGFibGVyYW5nZTo1ZWE0NzU0OTAwODk0YmY1OTU0Y2E2MTIzNTVmMjBjMF8wLTAtMS0xLTA_74455b07-a0e4-4ab9-bebd-dffd4f4938c4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6NWVhNDc1NDkwMDg5NGJmNTk1NGNhNjEyMzU1ZjIwYzAvdGFibGVyYW5nZTo1ZWE0NzU0OTAwODk0YmY1OTU0Y2E2MTIzNTVmMjBjMF8xLTAtMS0xLTA_7bd8de1d-141b-443c-b791-adad81304aac">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6NWVhNDc1NDkwMDg5NGJmNTk1NGNhNjEyMzU1ZjIwYzAvdGFibGVyYW5nZTo1ZWE0NzU0OTAwODk0YmY1OTU0Y2E2MTIzNTVmMjBjMF8yLTAtMS0xLTA_4dcbc2c8-ef50-43dc-adc1-fdb9012fe544">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6NWVhNDc1NDkwMDg5NGJmNTk1NGNhNjEyMzU1ZjIwYzAvdGFibGVyYW5nZTo1ZWE0NzU0OTAwODk0YmY1OTU0Y2E2MTIzNTVmMjBjMF8zLTAtMS0xLTA_a6a3b746-69b8-4dfa-b913-c559ef0a54ec">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6YmNjNzA2YjhkZGVkNDA2NGEwNjU1ZmZmNzMzZmZhYjAvdGFibGVyYW5nZTpiY2M3MDZiOGRkZWQ0MDY0YTA2NTVmZmY3MzNmZmFiMF8xLTAtMS0xLTA_c944e63a-a39d-4906-86b5-a3e7c8048cf8">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6YmNjNzA2YjhkZGVkNDA2NGEwNjU1ZmZmNzMzZmZhYjAvdGFibGVyYW5nZTpiY2M3MDZiOGRkZWQ0MDY0YTA2NTVmZmY3MzNmZmFiMF8xLTMtMS0xLTA_f7faed48-e5c4-4b8c-8cc4-6bc7e9797045">VRDN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGFibGU6YmNjNzA2YjhkZGVkNDA2NGEwNjU1ZmZmNzMzZmZhYjAvdGFibGVyYW5nZTpiY2M3MDZiOGRkZWQ0MDY0YTA2NTVmZmY3MzNmZmFiMF8xLTUtMS0xLTA_027b48b2-3df6-4053-a838-03c8557b93b3">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </span></div><div style="margin-top:10pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i33c0b296012c42c68ff8b4144955c280_D20210423-20210423" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAzMGMzMDFlZDU1NDQ2MDU4MzVhNjE3M2E3NjdjYzBiL3NlYzowMzBjMzAxZWQ1NTQ0NjA1ODM1YTYxNzNhNzY3Y2MwYl8xL2ZyYWc6N2Q0MTljODE4MWY4NGEzZDhiNTg5ODViNTM4ODBmNjYvdGV4dHJlZ2lvbjo3ZDQxOWM4MTgxZjg0YTNkOGI1ODk4NWI1Mzg4MGY2Nl8xMjM3_1f0246fa-4309-45a6-b5e5-6e1f1aed1b47">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i030c301ed5544605835a6173a767cc0b_4"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.01 Entry into a Material Definitive Agreement.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;23, 2021, Viridian Therapeutics, Inc. (the &#8220;Company&#8221;) entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (the &#8220;Agent&#8221;), pursuant to which the Company may offer and sell shares of the Company&#8217;s common stock having an aggregate offering price of up to $50,000,000, from time to time, in &#8220;at the market&#8221; offerings through the Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any shares of common stock sold under the Sale Agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not obligated to sell, and the Agent is not obligated to buy or sell, any shares of common stock under the Sale Agreement. No assurance can be given that the Company will sell any shares of common stock under the Sale Agreement, or, if it does, as to the price or amount of shares of common stock that it sells or the dates when such sales will take place.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Sale Agreement, the Company agreed to indemnify the Agent against certain liabilities, including under the Securities Act of 1933, as amended, or to contribute payments that the Agent may be required to make because of such liabilities.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of common stock sold pursuant to the Sale Agreement will be offered pursuant to a shelf registration statement on Form S-3 (File No. 333&#8209;237413), which became effective on April 14, 2020. The Company filed a prospectus supplement with the U.S. Securities and Exchange Commission on April 23, 2021 in connection with the offer and sale of shares of the Company&#8217;s common stock pursuant to the Sale Agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Sale Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Sale Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sale Agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the opinion of Gibson, Dunn &amp; Crutcher LLP relating to the validity of the shares of common stock that may be sold pursuant to the Sale Agreement is filed herewith as Exhibit 5.1.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-bottom:12pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.433%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202104238kex11.htm">1.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Open Market Sale Agreement, dated April 23, 2021, by and between Viridian Therapeutics, Inc. and Jefferies LLC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202104238kex51.htm">5.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Opinion of Gibson, Dunn &amp; Crutcher LLP.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202104238kex51.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Gibson, Dunn &amp; Crutcher LLP (contained in Exhibit 5.1). </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i030c301ed5544605835a6173a767cc0b_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.869%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Viridian Therapeutics, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April 23, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jason A. Leverone</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason A. Leverone</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer, and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "vrdn-20210423.htm", "description": "8-K", "secsgml_size_bytes": 42895}]
{"company-data": {"conformed-name": "Viridian Therapeutics, Inc.\\DE", "cik": "0001590750", "assigned-sic": "8071", "irs-number": "471187261", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36483", "film-number": "21850814"}, "business-address": {"street1": "6200 LOOKOUT ROAD", "city": "BOULDER", "state": "CO", "zip": "80301", "phone": "303-531-5952"}, "mail-address": {"street1": "6200 LOOKOUT ROAD", "city": "BOULDER", "state": "CO", "zip": "80301"}, "former-company": [{"former-conformed-name": "MIRAGEN THERAPEUTICS, INC.", "date-changed": "20170213"}, {"former-conformed-name": "MIRAGEN THERAPEUTICS, INC.", "date-changed": "20170213"}, {"former-conformed-name": "SIGNAL GENETICS, INC.", "date-changed": "20140710"}]}
vrdn-20210423
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 23, 2021
VIRIDIAN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-36483
47-1187261
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
6200 Lookout Rd.
Boulder,
CO
80301
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (
720
)
643-5200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.01 par value
VRDN
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On April 23, 2021, Viridian Therapeutics, Inc. (the "Company") entered into an Open Market Sale Agreement
SM
(the "Sale Agreement") with Jefferies LLC (the "Agent"), pursuant to which the Company may offer and sell shares of the Company's common stock having an aggregate offering price of up to $50,000,000, from time to time, in "at the market" offerings through the Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the Agent. The Agent will receive a commission from the Company of 3.0% of the gross proceeds of any shares of common stock sold under the Sale Agreement.
The Company is not obligated to sell, and the Agent is not obligated to buy or sell, any shares of common stock under the Sale Agreement. No assurance can be given that the Company will sell any shares of common stock under the Sale Agreement, or, if it does, as to the price or amount of shares of common stock that it sells or the dates when such sales will take place.
In the Sale Agreement, the Company agreed to indemnify the Agent against certain liabilities, including under the Securities Act of 1933, as amended, or to contribute payments that the Agent may be required to make because of such liabilities.
The shares of common stock sold pursuant to the Sale Agreement will be offered pursuant to a shelf registration statement on Form S-3 (File No. 333‑237413), which became effective on April 14, 2020. The Company filed a prospectus supplement with the U.S. Securities and Exchange Commission on April 23, 2021 in connection with the offer and sale of shares of the Company's common stock pursuant to the Sale Agreement.
A copy of the Sale Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Sale Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sale Agreement.
A copy of the opinion of Gibson, Dunn & Crutcher LLP relating to the validity of the shares of common stock that may be sold pursuant to the Sale Agreement is filed herewith as Exhibit 5.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Exhibit Description
1.1
Open Market Sale Agreement, dated April 23, 2021, by and between Viridian Therapeutics, Inc. and Jefferies LLC.
5.1
Opinion of Gibson, Dunn & Crutcher LLP.
23.1
Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1).
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Viridian Therapeutics, Inc.
Date: April 23, 2021
By:
/s/ Jason A. Leverone
Jason A. Leverone
Chief Financial Officer, Treasurer, and Secretary